DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis.

Abstract

Four novel oral DNA vaccines provide long-lived protection against melanoma, colon, breast, and non-small cell lung carcinoma in mouse model systems. The vaccines are delivered by attenuated Salmonella typhimurium to secondary lymphoid organs and are directed against targets such as carcinoembryonic antigen, tyrosine-related protein, vascular endothelial growth factor receptor-2 [also called fetal liver kinase-1 (FLK-1)], and transcription factor Fos-related antigen-1 (Fra-1). The FLK-1 and Fra-1 vaccines are effective in suppressing angiogenesis in the tumor vasculature. All four vaccines are capable of inducing potent cell-mediated protective immunity, breaking peripheral T-cell tolerance against these self-antigens resulting in effective suppression of tumor growth and metastasis. It is anticipated that such research efforts will contribute toward the rational design of future DNA vaccines that will be effective for prevention and treatment of human cancer.

• Authors: Ralph A Reisfeld, Andreas G Niethammer, Yunping Luo, Rong Xiang
• Journal: Immunological reviews (Immunol Rev) Vol. 199 Pg. 181-90 (Jun 2004) ISSN: 0105-2896 [Print] England
• PMID: 15233734 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Cancer Vaccines
• Carcinoembryonic Antigen
• Proto-Oncogene Proteins c-fos
• Vaccines, DNA
• fos-related antigen 1
• Vascular Endothelial Growth Factor Receptor-2

Topics

• Administration, Oral
• Animals
• Cancer Vaccines (administration & dosage, immunology, therapeutic use)
• Carcinoembryonic Antigen (genetics, immunology)
• Mice
• Neoplasm Metastasis (therapy)
• Neoplasms (immunology, therapy)
• Neovascularization, Pathologic (therapy)
• Proto-Oncogene Proteins c-fos (genetics, immunology)
• Salmonella typhimurium (metabolism)
• Vaccines, DNA (administration & dosage, immunology, therapeutic use)
• Vascular Endothelial Growth Factor Receptor-2 (genetics, immunology)